PARTNERSHIP OPPORTUNITES

Achieving our goals hinges greatly on the invaluable support and collaboration of organisations like yours.

The Myeloma Summit will use its best endeavours to deliver a fantastic event that meets sponsor expectations and provides value for your investment alongside a memorable occasion for you and the other attendees. 

On behalf of our Conference Convenors we sincerely thank you for your continued support of the Myeloma Summit 2026 being held 6-8 August at the Copthorne Hotel and Resort Queenstown. 

If you are interested in joining us as a partner at conference, please contact Paula Armstrong Paula@fp2.co.nz today for more information. 

GOLD PARTNERS

At GSK we prevent and treat disease with specialty medicines, vaccines and general medicines. We're a focused global biopharma company with strong momentum and big ambitions. We're pursuing research and development across four core therapeutic areas: respiratory, immunology and inflammation; oncology & haematology; HIV; and infectious diseases. Our purpose at GSK is to unite science, technology and talent to get ahead of disease together.Find out more at New Zealand | GSK

Johnson & Johnson is a global healthcare leader, committed to solving the toughest health challenges and transforming lives through research, development, manufacture and distribution of medicines and medical technologies. The company’s Innovative Medicine business advances breakthrough science and develops transformational treatments in areas like oncology, immunology, neuroscience, and cardiopulmonary. In MedTech, the company is focused on developing and delivering cardiovascular, surgery, and vision solutions. Visit jnj.com to learn more.

BRONZE PARTNERS

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 304 million people worldwide.

Binding Site, part of Thermo Fisher Scientific, delivers specialized diagnostic solutions to support clinicians in the diagnosis and monitoring of plasma cell disorders and immune diseases.

Built on over 40 years of scientific expertise, its portfolio includes the widely trusted Freelite® assays for serum free light chain measurement and the EXENT® GAM assay, which uses MALDI-ToF mass spectrometry to sensitively detect and quantify M-proteins. Together, these complementary technologies enable more precise assessment of monoclonal gammopathies, supporting confident clinical decision-making.

 Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation.

Roche New Zealand operates across two businesses, Pharmaceuticals and Diagnostics. Our​ ​ aim is to enable New Zealanders access to our medicines and diagnostic tests to detect​ ​ illnesses early, and to treat them with life-saving and life-changing medicines.​ ​ We have one purpose: to do now what patients need next. roche.co.nz​